Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 17/20 | 0.41 |
| ▸ | HTR2B | P41595 | 12/20 | 0.37 |
| ▸ | HTR2A | P28223 | 8/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797394 | 0.81 | HTR2C (0.61) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL18016885 | 0.79 | HTR2C (0.63) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL25004709 | 0.79 | HTR2C (0.41) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL25053928 | 0.79 | HTR2C (0.41) | HTR2CHTR2BHTR2AMAOBKDM1A | |
| SCHEMBL18016892 | 0.78 | HTR2C (0.59) | HTR2CHTR2BHTR2AKDM1ASLC6A2 | |
| SCHEMBL18016867 | 0.78 | HTR2C (0.59) | HTR2CHTR2BHTR2AKDM1ASLC6A2 | |
| SCHEMBL18016880 | 0.78 | HTR2C (0.58) | HTR2CHTR2BHTR2ASLC6A3 | |
| SCHEMBL18016878 | 0.78 | HTR2C (0.58) | HTR2CHTR2BHTR2ASLC6A3 | |
| SCHEMBL15255147 | 0.75 | HTR2C (0.64) | HTR2CHTR2BHTR2AMAOBSLC6A2 | |
| SCHEMBL13635493 | 0.75 | HTR2C (0.64) | HTR2CHTR2BHTR2AMAOBSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR2C 4514/4885HTR2B 3829/4885HTR2A 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.